DaVita (NYSE:DVA) Shares Cross Above 200-Day Moving Average on Analyst Downgrade

DaVita Inc. (NYSE:DVA)’s stock price passed above its two hundred day moving average during trading on Monday after Wall Street Zen upgraded the stock from a hold rating to a buy rating. The stock has a two hundred day moving average of $128.91 and traded as high as $150.22. DaVita shares last traded at $150.0610, with a volume of 640,484 shares changing hands.

Several other research firms have also commented on DVA. Weiss Ratings reaffirmed a “hold (c)” rating on shares of DaVita in a research report on Monday, December 29th. Truist Financial set a $158.00 target price on DaVita in a research report on Thursday, February 5th. Barclays lifted their target price on DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 3rd. Zacks Research raised DaVita from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. Finally, UBS Group lifted their target price on DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a research report on Wednesday, February 4th. One research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $155.80.

Hedge Funds Weigh In On DaVita

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Hsbc Holdings PLC boosted its position in shares of DaVita by 71.7% during the fourth quarter. Hsbc Holdings PLC now owns 133,080 shares of the company’s stock worth $15,110,000 after buying an additional 55,553 shares during the period. Rockefeller Capital Management L.P. boosted its position in shares of DaVita by 26.7% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,049 shares of the company’s stock worth $119,000 after buying an additional 221 shares during the period. Corient Private Wealth LLC boosted its position in shares of DaVita by 22.5% during the fourth quarter. Corient Private Wealth LLC now owns 27,559 shares of the company’s stock worth $3,131,000 after buying an additional 5,069 shares during the period. Sankala Group LLC acquired a new position in shares of DaVita during the fourth quarter worth approximately $39,000. Finally, Virtu Financial LLC acquired a new position in shares of DaVita during the fourth quarter worth approximately $451,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Price Performance

The stock has a market cap of $9.92 billion, a P/E ratio of 14.99, a PEG ratio of 0.51 and a beta of 0.92. The company has a fifty day moving average of $147.22 and a 200 day moving average of $129.19.

DaVita (NYSE:DVA) last announced its earnings results on Monday, February 2nd. The company reported $3.40 EPS for the quarter, topping the consensus estimate of $3.24 by $0.16. The firm had revenue of $3.62 billion for the quarter, compared to analysts’ expectations of $3.51 billion. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The firm’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.24 earnings per share. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. As a group, analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.